Recently published phase III trials involving interleukin-2, ipilimumab and vemurafenib redefine 'standard-of-care' for metastatic melanoma and demonstrate improved survival compared with dacarbazine. All three therapies are potential first-line options for patients with metastatic melanoma, with optimal treatment strategies evolving based on tumor mutation status, disease burden, performance status and comorbidities.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
BMC Complementary and Alternative Medicine Open Access 26 July 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Garbe, C., Eigentler, T. K., Keilholz, U., Hauschild, A. & Kirkwood, J. M. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5–24 (2011).
Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999).
Schwartzentruber, D. J. et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119–2127 (2011).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 471, 949–954 (2002).
Ribas, A. et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma [abstract]. J. Clin. Oncol. 29 (Suppl.), a8509 (2011).
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Kwon, E. J., Kish, L. S. & Jaworsky, C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J. Am. Acad. Dermatol. 61, 522–527 (2009).
Smalley, K. S. & Sondak, V. K. Melanoma—an unlikely poster child for personalized cancer therapy. N. Engl. J. Med. 363, 876–878 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sondak, V., Flaherty, L. Improved outcomes for patients with metastatic melanoma. Nat Rev Clin Oncol 8, 513–515 (2011). https://doi.org/10.1038/nrclinonc.2011.119
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.119
This article is cited by
-
Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors
Modern Pathology (2014)
-
The Ever-Evolving Landscape for Detection of Early Melanoma: Challenges and Promises
Journal of Investigative Dermatology (2013)
-
HLA-A*0201 + Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients
Journal of Investigative Dermatology (2012)
-
Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
BMC Complementary and Alternative Medicine (2012)
